Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03392168 · ClinicalTrials.gov registry record · Phase 1
Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis
A Phase 1 study, sponsored by Arcutis Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
NCT03392168 is a Phase 1 study that has completed, run by Arcutis Biotherapeutics. The registered enrollment target is 91 participants.
The verdict
NCT03392168, a Phase 1 study, has completed, sponsored by Arcutis Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
Study Summary
This study assessed the safety and pharmacokinetics (PK) of a single dose application of ARQ-151 cream 0.5% to 25 cm\^2 of psoriatic plaque(s) (Cohort 1). The study also assessed the safety, PK and efficacy of ARQ-151 cream 0.5% vs vehicle and ARQ-151 cream 0.15% vs vehicle applied once a day for 28 days to individuals with 0.5% to 5.0% body surface area (BSA) of chronic plaque psoriasis (Cohort 2).
Interventions
- DRUG ARQ-151 cream 0.15%
- DRUG ARQ-151 cream 0.5%
- DRUG ARQ-151 vehicle cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2017-12-11 |
| Est. Completion | 2018-05-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03392168
The ClinicalTrials.gov registry entry for NCT03392168 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcutis Biotherapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ARQ-151 cream 0.15% is the first listed.
NCT03392168 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03392168 about?
NCT03392168 is a clinical study titled "Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis". This study assessed the safety and pharmacokinetics (PK) of a single dose application of ARQ-151 cream 0.5% to 25 cm\^2 of psoriatic plaque(s) (Cohort 1). The study also assessed the safety, PK and efficacy of ARQ-151 cream 0.5% vs vehicle and ARQ-151 cream 0.15% vs vehicle applied once a day for 28...
What is the current status of trial NCT03392168?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2017-12-11. Estimated completion is 2018-05-02.
What interventions are being tested in trial NCT03392168?
The interventions under investigation include: ARQ-151 cream 0.15% (DRUG), ARQ-151 cream 0.5% (DRUG), ARQ-151 vehicle cream (DRUG).
Who is sponsoring clinical trial NCT03392168?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.